[1] S. Pai, O. A. Bamodu, Y. K. Lin et al., "CD47-SIRPalpha signaling induces epithelial-mesenchymal transition and cancer stemness and links to a poor prognosis in patients with oral squamous cell carcinoma," Cells, vol. 8, no. 12, pp. 1658, 2019.
[2] K. D. Shield, J. Ferlay, A. Jemal et al., "The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012," CA Cancer J Clin, vol. 67, no. 1, pp. 51-64, 2017.
[3] E. Ivaldi, D. Di Mario, A. Paderno et al., "Postoperative radiotherapy (PORT) for early oral cavity cancer (pT1-2, N0-1): A review," Crit Rev Oncol Hematol, vol. 143, pp. 67-75, 2019.
[4] A. Lindemann, H. Takahashi, A. A. Patel, A. A. Osman, and J. N. Myers, "Targeting the DNA damage response in OSCC with TP53 mutations," J Dent Res, vol. 97, no. 6, pp. 635-644, 2018.
[5] H. Dan, S. Liu, J. Liu et al., "RACK1 promotes cancer progression by increasing the M2/M1 macrophage ratio via the NF-kappaB pathway in oral squamous cell carcinoma," Mol Oncol, vol. 14, no. 4, pp. 795-807, 2020.
[6] M. Kamat, B. D. Rai, R. S. Puranik, and U. V. Datar, "A comprehensive review of surgical margin in oral squamous cell carcinoma highlighting the significance of tumor-free surgical margins," J Cancer Res Ther, vol. 15, no. 3, pp. 449-454, 2019.
[7] H. Yang, C. Mo, Y. Xun et al., "Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma," Am J Transl Res, vol. 11, no. 4, pp. 2370-2381, 2019.
[8] E. Sick, A. Jeanne, C. Schneider et al., "CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest," Br J Pharmacol, vol. 167, no. 7, pp. 1415-1430, 2012.
[9] A. S. Folkes, M. Feng, J. M. Zain et al., "Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience," Curr Opin Oncol, vol. 30, no. 5, pp. 332-337, 2018.
[10] S. B. Willingham, J. P. Volkmer, A. J. Gentles et al., "The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors," Proc Natl Acad Sci U S A, vol. 109, no. 17, pp. 6662-6667, 2012.
[11] H. L. Matlung, K. Szilagyi, N. A. Barclay, and T. K. van den Berg, "The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer," Immunol Rev, vol. 276, no. 1, pp. 145-164, 2017.
[12] S. Jain, A. Van Scoyk, E. A. Morgan et al., "Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas," Blood, vol. 134, no. 17, pp. 1430-1440, 2019.
[13] K. Weiskopf, "Cancer immunotherapy targeting the CD47/SIRPalpha axis," Eur J Cancer, vol. 76, pp. 100-109, 2017.
[14] Y. Huang, Y. Ma, P. Gao, and Z. Yao, "Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy," J Thorac Dis, vol. 9, no. 2, pp. E168-E174, 2017.
[15] H. Zhao, X. Zhang, Z. Han, Z. Wang, and Y. Wang, "Plasma anti-BIRC5 IgG may be a useful marker for evaluating the prognosis of nonsmall cell lung cancer," FEBS Open Bio, vol. 8, no. 5, pp. 829-835, 2018.
[16] R. Schwartz-Albiez, R. C. Monteiro, M. Rodriguez, C. J. Binder, and Y. Shoenfeld, "Natural antibodies, intravenous immunoglobulin and their role in autoimmunity, cancer and inflammation," Clin Exp Immunol, vol. 158 Suppl 1, no. Suppl 1, pp. 43-50, 2009.
[17] S. Panda, J. L. Ding, "Natural antibodies bridge innate and adaptive immunity," J Immunol, vol. 194, no. 1, pp. 13-20, 2015.
[18] L. Ye, S. Guan, C. Zhang et al., "Circulating autoantibody to FOXP3 may be a potential biomarker for esophageal squamous cell carcinoma," Tumour Biol, vol. 34, no. 3, pp. 1873-1877, 2013.
[19] H. Zhao, X. Zhang, Z. Han et al., "Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer," Sci Rep, vol. 8, no. 1, pp. 9847, 2018.
[20] Y. Wang, Z. Yan, Y. Huang et al., "Study of natural IgG antibodies against vascular endothelial growth factor receptor 1 in hepatocellular carcinoma," Am J Cancer Res, vol. 7, no. 3, pp. 603-609, 2017.
[21] X. Liu, Z. Huang, Z. He et al., "A study of natural IgG antibodies against ATP-binding cassette subfamily C member 3 in oral squamous cell carcinoma," J Cancer Res Ther, vol. 15, no. 4, pp. 921-926, 2019.
[22] R. Whelan, D. St Clair, C. J. Mustard, P. Hallford, and J. Wei, "Study of novel autoantibodies in schizophrenia," Schizophr Bull, vol. 44, no. 6, pp. 1341-1349, 2018.
[23] C. Li, R. Whelan, H. Yang et al., "Anti-TSNARE1 IgG plasma levels differ by sex in patients with schizophrenia in a Chinese population," FEBS Open Bio, vol. 9, no. 10, pp. 1705-1712, 2019.
[24] W. Cai, C. Qiu, H. Zhang et al., "Detection of circulating natural antibodies to inflammatory cytokines in type-2 diabetes and clinical significance," J Inflamm (Lond), vol. 14, pp. 24, 2017.
[25] Y. Jin, S. Guan, L. Liu et al., "Anti-p16 autoantibodies may be a useful biomarker for early diagnosis of esophageal cancer," Asia Pac J Clin Oncol, vol. 11, no. 4, pp. e37-41, 2015.
[26] H. Zhao, X. Zhang, Z. Han, and Y. Wang, "Circulating anti-p16a IgG autoantibodies as a potential prognostic biomarker for non-small cell lung cancer," FEBS Open Bio, vol. 8, no. 11, pp. 1875-1881, 2018.
[27] C. Chen, Y. Huang, C. Zhang et al., "Circulating antibodies to p16 protein-derived peptides in breast cancer," Mol Clin Oncol, vol. 3, no. 3, pp. 591-594, 2015.
[28] Y. Huang, C. Zhang, C. Chen et al., "Investigation of circulating antibodies to ANXA1 in breast cancer," Tumour Biol, vol. 36, no. 2, pp. 1233-1236, 2015.
[29] L. Liu, N. Liu, B. Liu et al., "Are circulating autoantibodies to ABCC3 transporter a potential biomarker for lung cancer?," J Cancer Res Clin Oncol, vol. 138, no. 10, pp. 1737-1742, 2012.
[30] X. Ye, X. Wang, R. Lu et al., "CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma," Oncol Lett, vol. 15, no. 6, pp. 9075-9080, 2018.
[31] B. W. Dai, Z. M. Yang, P. Deng et al., "HOXC10 promotes migration and invasion via the WNT-EMT signaling pathway in oral squamous cell carcinoma," J Cancer, vol. 10, no. 19, pp. 4540-4551, 2019.
[32] J. P. Joseph, M. K. Harishankar, A. A. Pillai, and A. Devi, "Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC," Oral Oncol, vol. 80, pp. 23-32, 2018.
[33] D. T. Rosenthal, H. Iyer, S. Escudero et al., "p38γ promotes breast cancer cell motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior," Cancer Res, vol. 71, no. 20, pp. 6338-6349, 2011.
[34] X. Liu, H. Kwon, Z. Li, and Y. X. Fu, "Is CD47 an innate immune checkpoint for tumor evasion?," J Hematol Oncol, vol. 10, no. 1, pp. 12, 2017.
[35] A. Veillette, J. Chen, "SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy," Trends Immunol, vol. 39, no. 3, pp. 173-184, 2018.
[36] M. C. Ochoa, L. Minute, I. Rodriguez et al., "Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells," Immunol Cell Biol, vol. 95, no. 4, pp. 347-355, 2017.
[37] R. Pio, L. Corrales, and J. D. Lambris, "The role of complement in tumor growth," Adv Exp Med Biol, vol. 772, pp. 229-262, 2014.
[38] S. Y. Wang, G. Weiner, "Complement and cellular cytotoxicity in antibody therapy of cancer," Expert Opin Biol Ther, vol. 8, no. 6, pp. 759-768, 2008.
[39] S. Meyer, J. H. Leusen, and P. Boross, "Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer," MAbs, vol. 6, no. 5, pp. 1133-1144, 2014.